Clinical Trials Logo

Resistant Cancer clinical trials

View clinical trials related to Resistant Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06347068 Not yet recruiting - Breast Cancer Clinical Trials

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Start date: July 2024
Phase: Phase 1
Study type: Interventional

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

NCT ID: NCT06158139 Not yet recruiting - Pancreas Cancer Clinical Trials

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.

NCT ID: NCT05889312 Not yet recruiting - Cancer Clinical Trials

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

Start date: September 2023
Phase:
Study type: Observational

Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.

NCT ID: NCT05718882 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).

NCT ID: NCT04292119 Recruiting - Lung Cancer Clinical Trials

Lorlatinib Combinations in Lung Cancer

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155

NCT ID: NCT03678883 Active, not recruiting - Cancer Clinical Trials

9-ING-41 in Patients With Advanced Cancers

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.